Medical device company Body Vision Medical reported on Friday the receipt of US Food and Drug Administration market clearance for the LungVision 2.0 System that allows real-time tool-in-lesion confirmation through C-Arm Based Tomography (CABT) to provide an accurate access to pulmonary nodules.
The company said the updated LungVision System, part of LungVision Platform, features real-time tool-in-lesion confirmation combined with seamless integration of LungVision Tool, a disposable lung navigation catheter with superb maneuverability. The combination allows access of any endotherapy accessories to small pulmonary nodules.
This US FDA approval is based on the outstanding results from the company's multicentre clinical trials in over 400 clinical procedures in the US. LungVision allows physicians to plan, visualise and track endobronchial tools inside the radiolucent lesions in real time. It instantly fuses intraoperative imaging with pre-operative CT.
From 19-21 May, the company will exhibit its LungVision 2.0 platform at the ATS Annual Meeting 2019 held in Dallas as well as feature two presentations of LungVision.
Krish Bhadra, MD, CHI Memorial Hospital, will present the strengths of artificial intelligence in navigational bronchoscopy. Daniel Nader, MD, Cancer Treatment Centers of America, will present the contribution of the LungVision Platform in fiducial marker placement to increase efficiency of SBRT radio surgery.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib